Inventor
JACKMAN ROBIN M
US12 patents
⚠️ This page may combine multiple inventors who share the name “JACKMAN ROBIN M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BIOMARIN PHARM INC
8 patentsUS8809009B2Aug 19, 2014
Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
BIOMARIN PHARM INC14 citations92
US9222120B2Dec 29, 2015
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
BIOMARIN PHARM INC13 citations89
US9915649B2Mar 13, 2018
Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA
BIOMARIN PHARM INC4 citations83
US9677116B2Jun 13, 2017
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
BIOMARIN PHARM INC4 citations83
US9340822B2May 17, 2016
Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
BIOMARIN PHARM INC12 citations83
US10260084B2Apr 16, 2019
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
BIOMARIN PHARM INC2 citations72
US10793894B2Oct 6, 2020
Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
BIOMARIN PHARM INC0 citations51
US10677786B2Jun 9, 2020
Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
BIOMARIN PHARM INC0 citations51
CRAWFORD BRETT E
2 patentsUS8232073B2Jul 31, 2012
Quantification of non-reducing end glycan residual compounds
CRAWFORD BRETT E35 citations94
US8771974B2Jul 8, 2014
Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder
CRAWFORD BRETT E16 citations91